ArticlePharmacotherapy2026
DILIConsult: A Multi-Agent Large Language Model Framework for Evaluating Drug-Induced Liver Injury in ICU Settings.
Article in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLarge language models (LLMs) can support clinical decision-making by parsing databases and extracting relevant information. However, evaluating drug-induced liver injury (DILI) often requires processing lengthy clinical histories alongside reference materials like LiverTox, which can exceed context lengths of conventional LLMs. Challenges such as information truncation hinder standard approaches like prompt engineering and retrieval-augmented generation (RAG). To address these limitations, this study introduces DILIConsult, an agentic LLM pipeline based on GPT-4, designed to intelligently parse clinical and drug information.
methodsTo develop DILIConsult, we compared GPT-4-Turbo versus GPT-4o for extracting DILI characteristics from LiverTox descriptions. We tested two approaches to analyzing cases of suspected DILI: full-length case analysis versus sequential drug-specific evaluations. We evaluated DILIConsult on cases of suspected DILI identified from the open source Medical Information Mart for Intensive Care-IV (MIMIC-IV) ICU dataset based on American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) criteria. Outputs from DILIConsult were compared against a panel of clinicians comprising an ICU pharmacist, an ICU junior attending physician, and an ICU resident. Responses were evaluated by two senior ICU attending physicians.
resultsUsing GPT-4o and a sequential approach demonstrated improved performance in the extraction of DILI characteristics and analysis of suspected DILI. DILIConsult achieved the best mean rank of 1.66 ± 0.75 in knowledge recall and ranked second for reasoning (2.00 ± 0.64) and reflection of current medical consensus (2.05 ± 0.62). DILIConsult ranked last with mean ranks of 2.07 ± 0.52 and 2.09 ± 0.72 for less omission of important information and content inaccuracy, respectively.
conclusionDILIConsult demonstrates the potential of LLMs to assist clinicians in evaluating DILI. The findings emphasize the importance of task division in LLM-driven workflows to minimize information loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.